Clinical Trial

Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry

Study acronym: IMPACTEndoAsia
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The treatment practices for endometrial cancer have significantly changed over the last two decades. Nowadays, in addition to standard pathology, additional tests are performed to understand the behaviour of tumour so that personalized treatment can be advised for every patient. This approach ensures that patients with good cancer cell features receive minimum essential radiotherapy or surgery treatment with fewer side effects, while those with poor cell features undergo more aggressive treatment to improve their chances of survival. However, this approach is not widely adopted in Asian countries. To address this, investigators are launching a project to gather data from various hospitals across Asia. The project aims to understand how different cancer cell factors impact treatment decisions and identify better ways to select additional treatment plans based on a patient's cancer cell features. The project will gather data from around 250-300 patients who were evaluated or treated between January 2021 and December 2023. It will run for two years to improve our understanding and gain insights into the best ways to treat endometrial cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-12.
Trial Details
NCT Number NCT07354087
Lead Sponsor Tata Memorial Hospital
Conditions Endometrial Cancer
Enrollment 300 participants
Start Date 2024-11-28
Primary Completion 2026-11-27 (estimated)
Study Completion 2026-11-27 (estimated)
Updated on ClinicalTrials.gov 2026-02-04